Quick answer: latest quarter results, by ticker or company name

Reported Q: Q4 2024 Rev YoY: +85.4% EPS YoY: +2.0% Move: +6.79%

Arctic Bioscience AS

ABS.OL

Kr.3.46 6.79%

Exchange OSL Sector Healthcare Industry Biotechnology

Q4 2024

Published: Dec 31, 2024

Company Status Snapshot

Fast view of the latest quarter outcome for ABS.OL

Reported

Report Date

Dec 31, 2024

Quarter Q4 2024

Revenue

13.60M

YoY: +85.4%

EPS

-0.48

YoY: +2.0%

Market Move

+6.79%

Previous quarter: Q3 2024

Follow this company to get upcoming quarter alerts automatically.

Earnings Highlights

Revenue of $13.60M up 85.4% year-over-year
EPS of $-0.48 increased by 2% from previous year
Gross margin of 26.5%
Net income of -12.21M
"" -

ABS.OL

Company ABS.OL

Period Q4 2024

Currency NOK

Report Type Quarterly Earnings

Generated Mar 30, 2026

Swipe to view all report sections

Executive Summary

Arctic Bioscience AS reported QQ4 2024 revenue of NOK 13.60 million, delivering a substantial year-over-year uplift of 85.35% driven by stronger top-line activity. Despite the revenue expansion, the company posted a meaningful operating loss with EBITDA at NOK -11.08 million and net income of NOK -12.21 million, underscoring a high burn-to-build phase typical of a development-stage biotechnology company coupled with substantial non-operational expenses. The quarterly results reflect a business still in investment mode, balancing development costs (R&D) against early-stage commercial activity from nutraceutical bulk ingredients under the ROMega brand.

Key Performance Indicators

Revenue

Increasing

13.60M

QoQ: 0.00% | YoY: 85.35%

Gross Profit

Increasing

3.61M

26.54% margin

QoQ: 0.00% | YoY: 78.32%

Operating Income

Increasing

-11.80M

QoQ: 0.00% | YoY: 9.21%

Net Income

Increasing

-12.21M

QoQ: 0.00% | YoY: 1.74%

EPS

Increasing

-0.48

QoQ: 0.00% | YoY: 2.04%

Revenue Trend

Margin Analysis

Financial Highlights

Revenue: NOK 13,599,915 in Q4-2024; YoY growth 85.35%; QoQ growth 0.00%. Gross Profit: NOK 3,609,941; Gross Margin 26.54%; YoY Gross Profit growth 78.32%; QoQ 0.00%. Operating Income: NOK -11,802,904; Operating Margin -8.68%; YoY change 9.21%; QoQ 0.00%. Net Income: NOK -12,208,446; Net Margin -8.98%; YoY change 1.74%; QoQ 0.00%. EBITDA: NOK -11,082,095; EBITDA Margin -0.81; YoY change 0.0%? (as per reported figure); Cash Flow: Operating cash flow NOK -9,877,537; Capex NOK -25,329,796; Free Cash Flow NOK -35,207,333. Balance Sheet: Cash and cash equivalents NOK 2,159,147; Total current assets NOK 57,885,963; Total assets NOK 279,741,030; Total liabilities NOK 69,010,267; Equity NOK 210,730,763. Liquidity & Leverage: Current ratio ~0.86; Total debt NOK 32,857,283; Net debt NOK 30,698,136. Earnings per share: -0.48 NOK (diluted).

Income Statement

Metric	Value	YoY Change	QoQ Change
Revenue	13.60M	85.35%	0.00%
Gross Profit	3.61M	78.32%	0.00%
Operating Income	-11.80M	9.21%	0.00%
Net Income	-12.21M	1.74%	0.00%
EPS	-0.48	2.04%	0.00%

Key Financial Ratios

Historical Earnings Comparison

Period	Revenue ($M)	EPS ($)	YoY Growth	Report
Q2 2025	18.70	-0.70	+37.5%	View
Q1 2025	9.35	-0.35	+8.7%	View
Q4 2024	13.60	-0.48	+85.4%	View
Q3 2024	13.60	-0.48	+85.4%	View

Arctic Bioscience AS (ABS.OL) Q4 2024 Earnings Report

Company Status Snapshot

Earnings Highlights

Executive Summary

Key Performance Indicators

Revenue Trend

Margin Analysis

Historical Earnings Comparison

More ABS.OL Quarterly Reports

ABS.OL

ABS.OL

ABS.OL

Q4 2024 Reports in Healthcare Sector

Related Financial Data

Sector Analysis: Healthcare

ABS.OL Full Profile

ABS.OL Financial Statements

Earnings Calendar